Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Keros Therapeutics (NASDAQ: KROS) with a Overweight rating.The analyst comments "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE